Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race

Ganesh M. Babulal; Sanne Franzen; Erin L. Abner; Jade Emily Smith; Esther van den Berg; Monica Rivera Mindt; Rozermarijn Lidewij van Bruchem-Visser; Lon S. Schneider; Niels D. Prins; Janne M. Papma

doi:10.1002/alz.12611

Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race

Ganesh M. Babulal, Sanne Franzen, Erin L. Abner, Jade Emily Smith, Esther van den Berg, Monica Rivera Mindt, Rozermarijn Lidewij van Bruchem-Visser, Lon S. Schneider, Niels D. Prins, Janne M. Papma

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English
Pages (from-to)	867-868
Number of pages	2
Journal	Alzheimer's and Dementia
Volume	18
Issue number	4
DOIs	https://doi.org/10.1002/alz.12611
State	Published - Apr 2022

Bibliographical note

Funding Information:
SF and JMP report a grant from The Netherlands Organisation for Health Research and Development/Alzheimer's Nederland (ZonMw Memorabel; grant number 733050834). JES reports a personal James B. Reynolds scholarship for foreign study. LSS reports a grant from NIH (P30 AG066530). GMB reports grants from NIH/NIA (R01AG068183, R01AG067428, A2021142S) and the BrightFocus Foundation (A2021142S). MRM is supported by grants from the NIA/NIH (R13 AG071313‐01, R01AG065110‐01A1, NIH/NIA 5U19AG024904‐14, NIH/NIA R01AG066471‐01A1), NIH/NIMH (U24MH100931‐03), NIH/NIA (5R24AG065163), National Science Foundation, the Genentech Health Equity 2020 Fund (G‐89294), and the Alzheimer's Association (AARGD‐16‐446038).

ASJC Scopus subject areas

Clinical Neurology
Geriatrics and Gerontology
Psychiatry and Mental health
Cellular and Molecular Neuroscience
Health Policy
Developmental Neuroscience
Epidemiology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/alz.12611

Cite this

@article{63dc86202d0348c598833e40a9e43b11,

title = "Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race",

author = "Babulal, {Ganesh M.} and Sanne Franzen and Abner, {Erin L.} and Smith, {Jade Emily} and {van den Berg}, Esther and Mindt, {Monica Rivera} and {van Bruchem-Visser}, {Rozermarijn Lidewij} and Schneider, {Lon S.} and Prins, {Niels D.} and Papma, {Janne M.}",

note = "Funding Information: SF and JMP report a grant from The Netherlands Organisation for Health Research and Development/Alzheimer's Nederland (ZonMw Memorabel; grant number 733050834). JES reports a personal James B. Reynolds scholarship for foreign study. LSS reports a grant from NIH (P30 AG066530). GMB reports grants from NIH/NIA (R01AG068183, R01AG067428, A2021142S) and the BrightFocus Foundation (A2021142S). MRM is supported by grants from the NIA/NIH (R13 AG071313‐01, R01AG065110‐01A1, NIH/NIA 5U19AG024904‐14, NIH/NIA R01AG066471‐01A1), NIH/NIMH (U24MH100931‐03), NIH/NIA (5R24AG065163), National Science Foundation, the Genentech Health Equity 2020 Fund (G‐89294), and the Alzheimer's Association (AARGD‐16‐446038). ",

year = "2022",

month = apr,

doi = "10.1002/alz.12611",

language = "English",

volume = "18",

pages = "867--868",

number = "4",

}

TY - JOUR

T1 - Diversity in Alzheimer's disease drug trials

T2 - Reflections on reporting and social construction of race

AU - Babulal, Ganesh M.

AU - Franzen, Sanne

AU - Abner, Erin L.

AU - Smith, Jade Emily

AU - van den Berg, Esther

AU - Mindt, Monica Rivera

AU - van Bruchem-Visser, Rozermarijn Lidewij

AU - Schneider, Lon S.

AU - Prins, Niels D.

AU - Papma, Janne M.

N1 - Funding Information: SF and JMP report a grant from The Netherlands Organisation for Health Research and Development/Alzheimer's Nederland (ZonMw Memorabel; grant number 733050834). JES reports a personal James B. Reynolds scholarship for foreign study. LSS reports a grant from NIH (P30 AG066530). GMB reports grants from NIH/NIA (R01AG068183, R01AG067428, A2021142S) and the BrightFocus Foundation (A2021142S). MRM is supported by grants from the NIA/NIH (R13 AG071313‐01, R01AG065110‐01A1, NIH/NIA 5U19AG024904‐14, NIH/NIA R01AG066471‐01A1), NIH/NIMH (U24MH100931‐03), NIH/NIA (5R24AG065163), National Science Foundation, the Genentech Health Equity 2020 Fund (G‐89294), and the Alzheimer's Association (AARGD‐16‐446038).

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85124536992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124536992&partnerID=8YFLogxK

U2 - 10.1002/alz.12611

DO - 10.1002/alz.12611

M3 - Letter

C2 - 35142024

AN - SCOPUS:85124536992

SN - 1552-5260

VL - 18

SP - 867

EP - 868

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 4

ER -

Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this